Total
0
Shares
Invex Therapeutics (ASX:IXC) - Chairman, Jason Loveridge
Chairman, Jason Loveridge
Source: GoingPublic.de
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Invex Therapeutics (IXC) signs an agreement for the commercialisation of its treatment for neurological conditions caused by intracranial pressure
  • The company has signed a long-term collaboration and manufacturing agreement with Peptron, for the development of Presedin.
  • The agreement will see the treatment manufactured and supplied globally to Invex from Peptron’s manufacturing facility in Korea, which can produce more than 48,000 vials of Presendin per month
  • Invex Therapeutics is up 14.7 per cent, trading at 78 cents at 1:13 pm AEST

Invex Therapeutics (IXC) has signed an agreement for the commercialisation of its treatment for neurological conditions caused by intracranial pressure.

The company has signed a long-term collaboration and manufacturing agreement with Peptron, for the development of Presedin. Peptron is a Korean-based biopharma company developing sustained-release peptide-based medicines with high technological barriers to treat chronic diseases.

Under the agreement, Peptron will provide Invex with access to its intellectual property and a defined price per dose for the supply of Presendin – initially for clinical studies, then the first 10 years following the first commercial sale.

Presendin is a treatment for people suffering from idiopathic intracranial hypertension (IIH). IIH results in disabling daily headaches and can compress the optic nerve. The treatment offers a reduced injection frequency and typically leads to greater patient compliance.

Presendin will be manufactured and supplied globally to Invex from Peptron’s manufacturing facility in Korea, which can produce more than 48,000 vials of Presendin per month.

Additionally, Invex has granted Peptron an exclusive license to commercialise it for idiopathic intracranial hypertension (IIH) in Korea.

Chairman of Invex Jason Loveridge said the collaboration was a significant step forward for the company.

“Peptron has years of experience in both the manufacture and clinical development of Exenatide and this collaboration significantly de-risks Invex’s development of Presendin in IIH, by providing access to both drug product as well as to Peptron’s critical and extensive data package and their manufacturing and technical expertise,” Dr Loveridge said.

“As a result, Invex will no longer need to undertake additional animal tolerability and human pharmacokinetic studies for Presendin, which reduces Invex’s development costs and risk and significantly expedites our planned Phase III registration study in IIH.”

Invex Therapeutics was up 14.7 per cent, trading at 78 cents at 1:13 pm AEST.

IXC by the numbers
More From The Market Herald
Zelira Therapeutics (ASX:ZLD) - CEO and MD, Dr Oludare Odumosu

" Zelira Therapeutics (ASX:ZLD) recieves funding from Quincy Street

Zelira Therapeutics (ZLD) has raised US$5 million (around A$6.68) from US family office fund, Quincy Street Capital.
Advanced Human Imaging (ASX:AHI) - CEO, Vlado Bosanac

" Advanced Human Imaging (ASX:AHI) pushes ahead with NASDAQ listing

Advanced Human Imaging (AHI) is pushing ahead with a planned NASDAQ listing, after filing a key form with the US Securities and Exchange
Opthea (ASX:OPT) - CEO and MD, Megan Baldwin

" Opthea (ASX:OPT) opens patient enrolment in Asia-Pacific

Opthea (OPT) has opened patient enrolment for its Phase 3 clinical program for the treatment of wet (neovascular) age-related macular degeneration (AMD) in

" TruScreen (ASX:TRU) highlights efficacy of cancer screening technology

TruScreen (TRU) says the results of a new study demonstrate its cervical cancer screening technology to be an effective alternative to other screening